Is the measurement of serum cytokeratin-18 useful for diagnosis or screening non-alcoholic steatohepatitis?

Hepatology Research

Volumn 44, Issue 8, 2014, Pages 827-828

  Yoneda, Masashi ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; BIOLOGICAL MARKER; CYTOKERATIN 18; PHOSPHOLIPASE; PHOSPHOLIPASE DOMAIN CONTAINING PROTEIN 3; UNCLASSIFIED DRUG;

APOPTOSIS; AREA UNDER THE CURVE; EDITORIAL; ELASTOGRAPHY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INFLAMMATORY INFILTRATE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER HISTOLOGY; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84904636644     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12250     Document Type: Editorial

References (21)

1. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
2. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28: 339-350.
3. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007; 11: 1-16.
4. Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988; 95: 1056-1062.
5. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.
6. Shimada M, Hashimoto E, Kaneda H, Noguchi S, Hayashi N. Nonalcoholic steatohepatitis: risk factors for liver fibrosis. Hepatol Res 2002; 24: 429-438.
7. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 18: 1221-1231.
8. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
9. Ratziu V, Giral P, Charlotte F etal. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.
10. Yoneda M, Yoneda M, Fujita K etal. Transient elastography in Patients with Nonalcoholic Fatty liver Disease (NAFLD). Gut 2007; 56: 1330-1331.
11. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-1078.
12. Malik R, Chang M, Bhaskar K etal. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2009; 24: 564-568.
13. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27-33.
14. Chen J, Zhu Y, Zheng Q, Jiang J. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: a meta-analysis. Hepatol Res 2013. doi: 10.1111/hepr.12197.
15. Guyatt GH, Oxman AD, Vist GE etal. GRADE: an emerging consensus on ratingquality of evidence and strength of recommendations. Br Med J 2008; 336: 924-926.
16. Galluzzi L, Maiuri MC, Vitale I etal. Cell death modalities: classification and pathophysiologicalimplications. Cell Death Differ 2007; 14: 1237-1243.
17. Kawaguchi T, Sumida Y, Umemura A etal. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS ONE 2012; 7: e38322.
18. Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009; 50: 2111-2116.
19. Hotta K, Yoneda M, Hyogo H, Ochi H, Mizusawa S. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet 2010; 11: 172.
20. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-1894.
21. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ. Genome-wide association analysis identifies variants associated with nonalcoholic Fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7: e1001324.